Abstract Poster Wall
2026 Kidney Cancer Research Summit
Abstract 24
A phase 1b/2 study of abemaciclib plus cabozantinib in immune checkpoint blockade-pretreated metastatic clear cell renal cell carcinoma and translocation-associated renal cell carcinoma
Sahil Doshi
Abstract 26
Outcomes of Systemic Therapy in Metastatic Translocation Renal Cell Carcinoma (tRCC): A Mayo Clinic Retrospective Study
Oluwatayo Adeoye
Abstract 31
Racial demographic reporting in clinical trials informing NCCN kidney cancer guidelines
Suhail Sapkota
Abstract 32
Inflamed eosinophilic phenotype predicts improved outcomes without excess immune-related adverse events in first-line ICI-treated metastatic renal cell carcinoma
Jack Masur
Abstract 33
Plasma proteomic profiling reveals SEZ6L2 as a novel biomarker in translocation renal cell carcinoma
Shane Killarney
Abstract 34
Belzutifan plus lenvatinib versus cabozantinib in post–PD-(L)1 renal cell carcinoma: Health-related quality-of-life outcomes in the phase 3 LITESPARK-011 study
Rodolfo Perini
Abstract 35
Targeting HIF2-driven Endogenous Retroviral Antigens for Immunotherapy in Kidney Cancer
Qinqin Jiang
Abstract 36
Clear cell renal cell carcinoma consensus transcriptomic programs reveal converging trajectories towards aggressive disease
Roy Elias
Abstract 37
Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases
Betul Gok Yavuz
Abstract 38
Prognostic Nutritional Index as a Predictor of Outcomes with Immune Checkpoint Inhibitors in Renal Cell Carcinoma
Kashyap Koul
Abstract 39
NPRL2 Expression Associates with Cytotoxic Immune Function Independent of Estimated Immune Cell Abundance in TCGA-KIRC
Muhammed Onel
Abstract 40
Ferritin-Dependent Iron Storage and Ferritinophagy Impact Ferroptosis Sensitivity in Chromophobe Renal Cell Carcinoma
Wafaa Bzeih
Abstract 41
Clinical Utility of Ultrasensitive ctDNA Detection Across the Renal Cell Carcinoma Disease Spectrum: A Multi-Cohort Retrospective Study
Ezra Blumenthal
Abstract 44
Ferroptosis Suppressor Protein 1 (FSP1) Drives Ferroptosis Resistance in Chromophobe Renal Cell Carcinoma
Steven Safi
Abstract 46
TKI resistance is associated with immune dysfunction in ccRCC
Xiande Liu
Abstract 47
Hemoglobin Drop Is An Early Predictor Of Erythropoietin Supplementation In VHL Syndrome Patients Under Belzutifan Treatment – First Report From The Real-Life BELIEVE-VHL Trial
Jose Claudio Casali-da-Rocha
Abstract 49
Effect of co-morbidity burden on the efficacy and tolerability of belzutifan in patients with metastatic renal cell carcinoma
Ali Hajj Ali
Abstract 50
Tumor–myeloid multicellular programs reveal ECM-associated macrophage polarization in ccRCC
Katsuhiro Ito
Abstract 51
Discovery of exhausted CD8+ T-cell states associated with clinical outcomes in renal cell carcinoma
Zhaochen Ye
Abstract 52
FGD1 Splice Variant in Clear Cell Renal Cell Carcinoma is a Novel Biomarker for Inferior Clinical Outcomes and Development of Brain and Bone Metastases.
Brandon Manley
Abstract 53
Neprectomy remodels peripheral myeloid cell states in renal cell carcinoma
Stephanie Schwartz
Abstract 55
Renal Cell Carcinoma tumor interstitial fluid possesses immunosuppressive and GPCR activating properties
Colin Laughlin
Abstract 57
Final Analysis of the TiNivo-2 Phase 3 Trial: Long-term Outcome of Tivozanib (Tivo) in patients with metastatic renal cell carcinoma (mRCC)
Bradley McGregor
Abstract 58
Baseline peripheral TCR diversity as a biomarker of response to first-line immunotherapy in metastatic clear cell renal cell carcinoma
Luigi Roca
Abstract 60
Germline platelet polygenic risk score predicts renal cell carcinoma survival via sustained thrombocytosis
Mustafa Saleh
Abstract 61
Differential Pattern of Disease Recurrence in Resected Renal Cell Carcinoma Patients Treated with Adjuvant Pembrolizumab versus Observation: A Propensity Score-Weighted Analysis
Liliana Ascione
Abstract 62
Patient Experience with Clinical Trials: Results from the International Kidney Cancer Coalition Global Patient Survey
Eric Jonasch
Abstract 64
GPR65 is a Novel Therapeutic Target Associated with Immune Exhaustion in Clear Cell Renal Cell Carcinoma
Nicholas Salgia
Abstract 66
Relationship between health-related quality of life and efficacy in the phase 3 LITESPARK-005 study of belzutifan versus everolimus in previously treated advanced clear cell renal cell carcinoma
Pooja Ghatalia
Abstract 67
Foundation model embeddings identify spatial restructuring associated with immunotherapy treatment derived from hemoxylin and eosin images
Alex Soupir
Abstract 68
LNK001 is a high-fidelity AND-logic-gated CAR T cell therapy that enables precision targeting of clear cell Renal Cell Carcinoma (ccRCC): Target discovery and validation for the ATHENA Phase 1 trial
Alexander Bankovich
Abstract 69
Spatial Proteomics Profiling Identifies Prognostic Biomarkers in Papillary Renal Cell Carcinoma
Jared Brewer
Abstract 70
Lymphocyte Hsp70 is a novel predictive biomarker for response to immune checkpoint inhibitors in metastatic renal cell carcinoma
Ethan Burns
Abstract 72
Time-of-day of immune checkpoint inhibitor infusion and overall survival in renal cell carcinoma: a real-world cohort analysis
Pablo Barrios
Abstract 75
Transcriptional correlates of ARNT expression and its impact on survival outcomes in clear-cell renal cell carcinoma (ccRCC)
Wassim Daoud Khatoun
Abstract 76
Defining Young-Onset Renal Cell Carcinoma (YORCC): a registry-based analysis of incidence trends
Wassim Daoud Khatoun
Abstract 77
Clinical predictors of local and atypical site recurrence after partial and radical nephrectomy for localized renal cell carcinoma
Rebecca Sager
Abstract 78
Dietary fructose intake and tumoral fructose-metabolism gene expression in metastatic renal cell carcinoma treated with immune checkpoint blockade
Antonio Ocejo
Abstract 79
Renal Cell Carcinoma Among Native American Patients in Oklahoma: A Single-Institution Experience From an NCI-Designated Cancer Center
Jafer Raza
Abstract 80
Real-world outcomes and clinicogenomic factors associated with response to tivozanib: a multi-center study
Jadon Fann
Abstract 81
Tumor-informed circulating tumor DNA monitoring in fumarate hydratase–deficient renal cell carcinoma
Antonio Ocejo
Abstract 82
Near-universal active surveillance for small renal mass patients: A novel 12-year clinical experience
Eric Kauffman
Abstract 83
Preclinical evaluation of LNK001: Stringent AND-gate fidelity and potent efficacy of a dual-antigen CAIX/ENPP3 CAR T cell therapy for clear cell renal cell carcinoma
Mark Wallet
Abstract 84
Phase 3 study to assess the safety and efficacy of 177Lu-girentuximab in advanced, relapsed or recurrent ccRCC (LUTEON; NCT07197580)
Sumanta Pal
Abstract 85
Phase 3 LITESPARK-033 (NCT07227402) study of belzutifan plus zanzalintinib versus cabozantinib for recurrent clear cell renal cell carcinoma during or after adjuvant anti–PD-(L)1 therapy
Toni K. Choueiri
Abstract 86
SPARCC: A single arm phase 2 study of sasanlimab, palbociclib and axitinib in metastatic renal cell carcinoma (NCT07123090).
Prateek Khanna
Abstract 88
PEAK-1 (NCT07011719): a randomized, double-blind, active-control phase 3 trial of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell renal cell carcinoma
Toni K Choueiri
Abstract 91
Developing a Platform for Human Translational Immunology Scientific Discovery in Kidney Cancer
Julia M Walker
Abstract 93
A Decade of Decline: Cytoreductive Nephrectomy Utilization in Metastatic Renal Cell Carcinoma Before and After the CARMENA Trial
Fumika Sano
Abstract 94
NPRL2 Loss Promotes Immunosuppression via Transcription of HIF1ɑ Variants and Glycolytic Reprogramming in Renal Cell Carcinoma
Hongchao He
Abstract 96
Clinical Utility of Tumor-Informed Circulating Tumor DNA for Disease Monitoring in Localized and Metastatic Renal Cell Carcinoma
Syed Saqib Balkhi
Abstract 97
Risk-Adapted Pembrolizumab Dosing Schedule to Mitigate Financial and Time Toxicity in Adjuvant Clear Cell Renal Cell Carcinoma
Syed Saqib Balkhi
Abstract 98
PRMT3 Promotes Clear Cell Renal Cell Carcinoma Growth Through Distinct Metabolic and Tumor Microenvironment Regulatory Mechanisms
Xingdi Ma
Abstract 99
Stabilin-1+ Tumor Endothelium Organizes a Perivascular Regulatory T-Cell Niche in Renal Cell Carcinoma
Yuexin Xu
Abstract 100
Older Statins Reduce Metastatic Potential in ccRCC: Mechanistic Validation of SIM (Selective Inhibitor of Metastasis) Development
Lily Wu
Abstract 101
Profilin-1 Promotes Chromophobe Renal Cell Carcinoma
Kaylee Montanari
Abstract 103
A Novel Mitochondrial DNA-Based Spatial Assay in Renal Cell Carcinoma Reveals Immune Exclusion of Mitochondrially Mutated Tumor Clones
Rachel Saxe
Abstract 104
Real-World Clinical Outcomes Among Renal Cell Carcinoma (RCC) Patients Following Nephrectomy in the Current Immuno-Oncology Era
Randall Lee
Abstract 105
KEAP1/NRF2 Pathway Somatic and Germline Mutations in RCC
Nicole Rittenhouse
Abstract 107
Host RNA Sequencing Identifies Reproducible Intratumoral Microbial Signals Across ccRCC Datasets
Jun Yang
Abstract 109
Hyperglycemia and Antihyperglycemic Medication Escalation Following Belzutifan in Renal Cell Carcinoma
Nonna Shakhnazaryan
Abstract 110
Patterns and Predictors of Recurrence Following Partial Nephrectomy for High-Grade Renal Cell Carcinoma
Rebecca Sager
Abstract 113
Metabolic Dysfunction Trajectory and the Risk of Clear Cell Renal Cell Carcinoma Among Individuals with Type 2 Diabetes Mellitus: A Large-Scale Real-World Cohort Study
Erick Mboya
ABSTRACT BOOK
Kidney Cancer Research Summit
July 23–24, 2026 – Boston, MA
Click the image above to download the Abstract Book.
Updated 07.22.26